Is MEDP a good stock to buy? We came across a bullish thesis on Medpace Holdings, Inc. on The Atomic Moat’s Substack by Rob H. | Atomic Moat. In this article, we will summarize the bulls’ thesis on MEDP. Medpace Holdings, Inc.’s share was trading at $514.90 as of April 21st. MEDP’s trailing and forward P/E were 33.70 and 30.12 respectively according to Yahoo Finance.
Nestor Rizhniak/Shutterstock.com
Medpace Holdings is positioned as a high-quality, founder-led clinical research organization (CRO) that functions as the outsourced execution engine for biotech drug development, handling everything from trial design and patient recruitment to regulatory navigation and data analysis. Unlike biotech firms, Medpace takes no scientific risk and instead earns steady, contract-based revenues, effectively “selling picks and shovels” to drug developers.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
The company benefits from strong economics, with FY2025 revenue of $2.53 billion and net income of $451.1 million, alongside premium ~21% operating margins and robust cash generation. Its model is supported by upfront customer payments and an asset-light structure, enabling significant free cash flow and aggressive share repurchases, which totaled over $900 million in FY2025.
However, the investment debate centers on sustainability. While Medpace generated strong growth, backlog expansion was modest, and book-to-bill stood at 1.05x, raising concerns that recent performance may be driven more by faster backlog conversion than underlying demand strength.
Given its heavy exposure to small and mid-sized biotech clients, the business remains sensitive to funding cycles, where any slowdown would first impact new awards and eventually revenue. Additionally, governance concerns around founder control and related-party transactions continue to weigh on valuation multiples despite solid operational performance.
Looking ahead, the key catalysts include sustained book-to-bill above 1.0x, accelerating backlog growth, and consistent execution within FY2026 guidance. If achieved, Medpace can continue compounding through strong cash flows and buybacks. Ultimately, the stock represents a high-quality compounding story, but one where valuation and returns depend heavily on demand durability and the continued funding of its aggressive capital return strategy.
Previously, we covered a bullish thesis on Medpace Holdings, Inc. (MEDP) by Compound & Fire in May 2025, which highlighted its strong margins, capital-light model, and long-term growth potential. MEDP’s stock price has appreciated by approximately 68.27% since our coverage. Rob H. | Atomic Moat shares a similar view but emphasizes on backlog sustainability, book-to-bill trends, and buyback durability.
Medpace Holdings, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 52 hedge fund portfolios held MEDP at the end of the fourth quarter which was 43 in the previous quarter. While we acknowledge the risk and potential of MEDP as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MEDP and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
